表紙
市場調査レポート

赤痢菌感染症 (細菌性赤痢) :パイプライン製品の分析

Shigella Infections (Shigellosis) - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 255959
出版日 ページ情報 英文 53 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
赤痢菌感染症 (細菌性赤痢) :パイプライン製品の分析 Shigella Infections (Shigellosis) - Pipeline Review, H1 2016
出版日: 2016年04月20日 ページ情報: 英文 53 Pages
概要

細菌性赤痢は、赤痢菌と称される細菌の一群により引き起こされる感染症です。通常は感染の1〜2日後に下痢や高熱、胃痙攣などが生じます。赤痢菌は人体の下痢の原因となるバクテリアの仲間であり、またヒトからヒトへと伝染していく微生物でもあります。症状が弱い場合には、抗生物質療法をしなくても急速に回復しますが、適切な抗生物質療法を施せば、赤痢菌を殺してより早く回復することができます。

当レポートでは、世界各国での赤痢菌感染症 (細菌性赤痢) 治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査しています。

イントロダクション

  • 調査範囲

赤痢菌感染症 (細菌性赤痢) の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

赤痢菌感染症 (細菌性赤痢) :企業で開発中の治療薬

赤痢菌感染症 (細菌性赤痢) :大学/機関で研究中の治療薬

赤痢菌感染症 (細菌性赤痢) :パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

赤痢菌感染症 (細菌性赤痢) :企業で開発中の製品

赤痢菌感染症 (細菌性赤痢) :大学/機関で研究中の製品

赤痢菌感染症 (細菌性赤痢) の治療薬開発に従事している企業

  • Anacor Pharmaceuticals, Inc.
  • GlaxoSmithKline Plc
  • Protein Potential, LLC

赤痢菌感染症 (細菌性赤痢) :治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

赤痢菌感染症 (細菌性赤痢) :最近のパイプライン動向

赤痢菌感染症 (細菌性赤痢) :休止中のプロジェクト

赤痢菌感染症 (細菌性赤痢) :開発が中止された製品

赤痢菌感染症 (細菌性赤痢) :製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7891IDB

Summary

Global Markets Direct's, 'Shigella Infections (Shigellosis) - Pipeline Review, H1 2016', provides an overview of the Shigella Infections (Shigellosis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Shigella Infections (Shigellosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Shigella Infections (Shigellosis) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Shigella Infections (Shigellosis)
  • The report reviews pipeline therapeutics for Shigella Infections (Shigellosis) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Shigella Infections (Shigellosis) therapeutics and enlists all their major and minor projects
  • The report assesses Shigella Infections (Shigellosis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Shigella Infections (Shigellosis)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Shigella Infections (Shigellosis)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Shigella Infections (Shigellosis) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Shigella Infections (Shigellosis) Overview
  • Therapeutics Development
    • Pipeline Products for Shigella Infections (Shigellosis) - Overview
    • Pipeline Products for Shigella Infections (Shigellosis) - Comparative Analysis
  • Shigella Infections (Shigellosis) - Therapeutics under Development by Companies
  • Shigella Infections (Shigellosis) - Therapeutics under Investigation by Universities/Institutes
  • Shigella Infections (Shigellosis) - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Shigella Infections (Shigellosis) - Products under Development by Companies
  • Shigella Infections (Shigellosis) - Products under Investigation by Universities/Institutes
  • Shigella Infections (Shigellosis) - Companies Involved in Therapeutics Development
    • Anacor Pharmaceuticals, Inc.
    • GlaxoSmithKline Plc
    • Microbiotix, Inc.
    • Protein Potential, LLC
    • Visterra, Inc.
  • Shigella Infections (Shigellosis) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (shigella + typhoid) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • 1790GAHB - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GVXNSD-133 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INX-201 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KKL-35 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SC-599 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SE-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • shigella vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • shigella vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • shigella vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • shigella vaccine 1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Shigetec - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Shigellosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VIS-GMN - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Shigella Infections (Shigellosis) - Recent Pipeline Updates
  • Shigella Infections (Shigellosis) - Dormant Projects
  • Shigella Infections (Shigellosis) - Discontinued Products
  • Shigella Infections (Shigellosis) - Product Development Milestones
    • Featured News & Press Releases
      • Jul 29, 2013: GlycoVaxyn Secures CHF 5.1 Million Strategic Translation Award From the Wellcome Trust to Finance Clinical Development of Shigella Vaccine
      • Feb 20, 2013: NIH-Funded Researchers Begin Trial of Shigella Vaccine Candidates
      • Jan 27, 2012: IVI Granted Two U.S. Patents On Dysentery Vaccine Inventions
      • Oct 08, 2010: GlycoVaxyn Phase I Clinical Study Shows Positive Data With Shigella Dysenteriae Vaccine Candidate Against Severe Diarrheal Disease
      • Feb 23, 2010: GlycoVaxyn Initiates Phase I Clinical Study with Bioconjugate Vaccine
      • Feb 15, 2007: IVI Scientists Develop New Laboratory Animal Model For Shigella
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Shigella Infections (Shigellosis), H1 2016
  • Number of Products under Development for Shigella Infections (Shigellosis) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Shigella Infections (Shigellosis) - Pipeline by Anacor Pharmaceuticals, Inc., H1 2016
  • Shigella Infections (Shigellosis) - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Shigella Infections (Shigellosis) - Pipeline by Microbiotix, Inc., H1 2016
  • Shigella Infections (Shigellosis) - Pipeline by Protein Potential, LLC, H1 2016
  • Shigella Infections (Shigellosis) - Pipeline by Visterra, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Shigella Infections (Shigellosis) Therapeutics - Recent Pipeline Updates, H1 2016
  • Shigella Infections (Shigellosis) - Dormant Projects, H1 2016
  • Shigella Infections (Shigellosis) - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Shigella Infections (Shigellosis), H1 2016
  • Number of Products under Development for Shigella Infections (Shigellosis) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top